Katexco was Founded by Prof Lawrence Steinman and Dr Jonathan Rothbard, who in Stanford developed over 26 medical research manuscripts together over the course of their careers and both of which have immense immunological therapy expertise. Prof Steinman’s research in his laboratory led to the development of the blockbuster drug Tysabri® (natalizumab), which is considered the most effective treatment for patients with multiple sclerosis and Crohn’s Disease. Moreover, the company’s Co-Founding, Prof Sir Marc Feldmann, discovered one of the most important discoveries of modern science and medicine, Anti-TNF therapy (the largest selling drug class globally) to treat inflammatory conditions such as Rheumatoid Arthritis.

Katexco is leveraging their pioneering experience in immunology to research and create orally active and available anti-inflammatory medicines.


The Katexco founders will continue their successful anti-inflammatory research with the α7 NAChR immunosuppressive receptor combined with CBD, to develop an orally available small molecule agonist to treat inflammatory diseases.

This will allow the treatment of conditions associated inflammation where significant unmet needs occur. Katexco's mission is clear, to improve patients’ lives with effective treatments and therapies.